VIRI
- Virios Therapeutics, Inc.
()
Overview
Company Summary
Virios Therapeutics, Inc. is a biotechnology company that focuses on the development and commercialization of novel antiviral therapies for the treatment of chronic diseases. Specifically, the company aims to address the need for effective therapies for diseases caused by the Epstein-Barr virus (EBV) and other related viral infections.
EBV is a common virus that infects a majority of the global population and can lead to various chronic illnesses, including certain types of cancers and autoimmune diseases. Virios Therapeutics is dedicated to leveraging its expertise in antiviral drug development to create innovative therapies that target and suppress the reactivation of EBV, thereby preventing or mitigating associated diseases.
The company's primary product candidate is called IMC-1, which is being developed as a combination therapy comprising famciclovir, a traditional antiviral drug, and celecoxib, an anti-inflammatory medication. IMC-1 has shown promising results in early clinical trials for the treatment of fibromyalgia, a condition that is believed to have a viral trigger, potentially EBV.
In addition to its focus on EBV-related diseases, Virios Therapeutics also aims to explore the application of its antiviral technologies in other chronic viral infections. The company's innovative approach, combining existing antiviral drugs with other agents, represents a unique strategy in the development of therapeutics for viral diseases.
Overall, Virios Therapeutics is committed to advancing the development of effective antiviral therapies to address unmet medical needs and improve the lives of patients suffering from chronic diseases associated with viral infections.